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Abstract
Summary Dosing regimens of oral bisphosphonates are
inconvenient and contribute to poor compliance. The bone
mineral density response to a once weekly delayed-release
formulation ofrisedronate given beforeorfollowing breakfast
was non-inferior to traditional immediate-release risedronate
given daily before breakfast. Delayed-release risedronate is a
convenient regimen for oral bisphosphonate therapy.
Introduction We report the results of a randomized,
controlled, clinical study assessing the efficacy and safety
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DOI 10.1007/s00198-011-1791-yof a delayed-release (DR) 35 mg weekly oral formulation of
risedronate that allows patients to take their weekly
risedronate dose before or immediately after breakfast.
Methods Women with postmenopausal osteoporosis were
randomly assigned to receive risedronate 5 mg immediate-
release (IR) daily (n=307) at least 30 min before breakfast,
or risedronate 35 mg DR weekly, either at least 30 min
before breakfast (BB, n=308) or immediately following
breakfast (FB, n=307). Bone mineral density (BMD), bone
turnover markers (BTMs), fractures, and adverse events
were evaluated. The primary efficacy variable was percent
change from baseline in lumbar spine BMD at Endpoint.
Results Two hundred fifty-seven subjects (83.7%) in the IR
daily group, 252 subjects (82.1%) in the DR FB weekly
group, and 258 subjects (83.8%) in the DR BB weekly
group completed 1 year. Both DR weekly groups were
determined to be non-inferior to the IR daily regimen.
Mean percent changes in hip BMD were similar across
groups. The magnitude of BTM response was similar
across groups; some statistical differences were seen that
were small and deemed by investigators to have no major
clinical importance. The incidence of adverse events
leading to withdrawal and serious adverse events were
similar across treatment groups. All three regimens were
well tolerated.
Conclusions Risedronate 35 mg DR weekly is similar in
efficacy and safety to risedronate 5 mg IR daily, and will
allow patients to take their weekly risedronate dose
immediately after breakfast.
Keywords Bone mineral density.Delayed-release.
Enteric-coated.Fracture risk.Osteoporosis.Risedronate.
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Introduction
Bisphosphonates are the standard of care for the treatment of
osteoporosis. Oral bisphosphonates are available in various
formulations with different dosing frequencies (i.e., daily,
weekly, and monthly) for patient convenience. However, all
oral bisphosphonates require patients to follow strict dosing
instructions to derive full benefit from the drug. Dosing
instructions outlined in product labels for oral bisphospho-
nates require that they be taken on an empty stomach at least
30 to 60 min before the first food, drink, or other medication
of the day [1–3]. Many patients perceive this requirement to
be inconvenient, and in one study, 33.5% stated they did not
wait for the minimum 30 min to eat after taking their
bisphosphonate [4].
The 30–60 min “before food or drink” requirement is
necessary for oral bisphosphonates due to decreased absorp-
tioninthe presenceoffood. Foodand drink (otherthan water)
contain calcium and other polyvalent cations that form
complexes with bisphosphonates, rendering them unavailable
for absorption [5]. In pivotal studies in which the efficacy of
oral bisphosphonates was established, 30–60 min “before
food or drink” dosing intervals were used to ensure the
amount of drug absorbed was adequate to produce a
clinically relevant efficacy response. The importance of the
“before food or drink” restriction is supported by pharmaco-
kinetic studies which have reported bioavailability to be
negligible [1]t o8 7 –90% lower in the fed state [6, 7]
compared to when the “before food or drink” period is
strictly followed. The clinical impact of this food effect was
demonstrated by Agrawal and colleagues who showed that
dosing risedronate between meals did not alter bone turnover
in nursing home residents [8]. Additionally, Kendler and
colleagues demonstrated that the lumbar spine bone mineral
density (BMD) response to risedronate 5 mg daily given
between meals and at least 2 h from a meal was smaller
(1.5% at 6 months) than when the same dose was
administered at least 30 min before breakfast (2.9%) [9].
Given the magnitude of reduction in absorption with food
and the high percentage of patients who admit not complying
with label instructions regarding “before food or drink”,
reduction in the benefits of bisphosphonate therapy becomes
a relevant clinical concern.
This study describes an innovative delayed-release (DR)
formulation of risedronate that ensures adequate bioavailabil-
ity of risedronate when taken with food. The 35 mg once-a-
week enteric-coated tablet delivers risedronate to sites beyond
the stomach where concentrations of substances that interfere
with its absorption are lower. In addition, a chelating agent
included in the formulation competitively binds cations such
as calcium that may be present in the area of absorption. This
new DR formulation eliminates the restriction to take
risedronate prior to the first food or drink in the morning and
ensures adequate bioavailability and pharmacological avail-
ability of risedronate.
To test the safety and efficacy of risedronate 35 mg
DR weekly in women with postmenopausal osteoporo-
sis, a randomized, double-blind, study was undertaken
comparing the 35 mg weekly DR tablet to the 5 mg
daily immediate-release (IR) tablet. This phase III
study was designed to test the non-inferiority (based
on the percent change in lumbar spine BMD from
baseline after 1 year) of the risedronate 35 mg DR
weekly formulation taken before or after breakfast
compared to the 5 mg daily IR dose taken per label.
Comparison to the 5 mg daily dose of risedronate IR
instead of the 35 mg weekly dose was performed to
meet regulatory guidelines for the approval of new
formulations of a previously approved drug. The
efficacy and safety results for the first year of the
study are reported here.
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Study design
This randomized, double-blind, active-controlled, parallel-
group study was conducted at 43 study centers in North
America, South America, and the European Union. The
first subject was screened in November 2007, and the last
subject observation for the first year of the study took place
in April 2009. The study was performed in accordance with
good clinical practice and the ethical principles that have
their origin in the Declaration of Helsinki. The protocol was
approved by the appropriate institutional review boards or
ethics committees, and the subjects gave written, informed
consent to participate.
Subjects
Women were eligible to enroll in the study if they were at
least 50 years of age, ambulatory, in generally good health,
postmenopausal (at least 5 years since last menses), had at
least three vertebral bodies in the lumbar spine (L1 to L4)
evaluable by densitometry (i.e., without fracture or degen-
erative disease), and had a lumbar spine or total hip BMD
corresponding to a T-score of −2.5 or lower or a T-score of
−2.0 or lower with at least one prevalent vertebral fracture
(T4 to L4). Exclusion criteria included contraindications to
oral bisphosphonate therapy, lumbar spine BMD
corresponding to a T-score of −5 or lower, use of
medications that could interfere with the study evaluations,
conditions that would interfere with the BMD measure-
ments, bilateral hip prostheses, body mass index greater
than 32 kg/m
2, allergy to bisphosphonates, history of cancer
in the last 5 years (excluding basal or squamous skin
cancers or successfully treated cervical cancer in situ), drug
or alcohol abuse, abnormal clinical laboratory measure-
ments, creatinine clearance less than 30 mL/min, hypo- or
hypercalcemia, history of hyperparathyroidism or hyper-
thyroidism (unless corrected), osteomalacia, and any previ-
ous or ongoing condition that the investigator judged could
prevent the subject from being able to complete the study.
Eligible subjects who gave consent were stratified by anti-
coagulant use (since fecal occult blood testing was
performed during the study) and randomly assigned in a
1:1:1 ratio to the three treatment groups.
Treatments
Subjects received oral risedronate 5 mg IR daily at least
30 min before breakfast or risedronate 35 mg DR once a
week, taken either at least 30 min before or immediately
following breakfast. All subjects took nine study tablets
each week: an IR study tablet daily plus a DR study tablet
before breakfast and another following breakfast on a single
specified day of the week. All placebo tablets were identical
in appearance to their corresponding 5 mg IR and 35 mg
DR active tablets and supplied in identical blister cards. All
tablets were taken with at least 4 oz of plain water, and
subjects were instructed to remain in an upright position for
at least 30 min after dosing. Compliance was assessed by
tablet counts; subjects were determined to be compliant if
they took at least 80% of the study tablets. Calcium
(1,000 mg/day) and vitamin D (800–1000 IU/day) were
supplied to all subjects who were instructed to take these
supplements with a meal other than breakfast and not with
the study medication.
Efficacy assessments
Dual energy X-ray absorptiometry (DXA) measurements of
lumbar spine and proximal femur were obtained at baseline
and after 26 and 52 weeks using instruments manufactured
by Lunar Corporation (GE Healthcare, Madison, WI, USA)
or Hologic (Waltham, MA, USA). DXA scans collected at
the clinical sites were sent to a central facility for quality
control and analysis (Synarc, San Francisco, CA, USA).
New incident vertebral fractures were assessed by semi-
quantitative morphometric analysis [10] of lateral thoracic
and lumbar spine radiographs collected at screening and
after 52 weeks. Radiographs were reviewed for quality and
analyzed for fracture at a central site (Synarc, San
Francisco, CA, USA).
Biochemical markers of bone turnover were assessed in
fasting samples at baseline and after 13, 26, and 52 weeks.
Serum bone-specific alkaline phosphatase (BAP) was
measured using an enzyme-linked immunosorbent assay
(MicroVue BAP, Metra Biosystems, Santa Clara, CA,
USA) on an automatic plate reader (VersaMax ELISA Plate
Reader, Molecular Devices Corp., Sunnyvale, CA, USA).
The intra- and interassay coefficients of variation for this
measurement were less than 4% and 8%, respectively. The
detection limit of the test was 0.7 IU/l and the limit of
quantitation was 140 IU/l. Urinary type-1 collagen cross-
linked N-telopeptide (NTX) was measured with an enzyme-
linked immunosorbent assay (Osteomark, Inverness Medi-
cal Professional Diagnostics, Princeton, NJ, USA) on an
automated plate reader (VersaMax ELISA Plate Reader,
Molecular Devices Corp., Sunnyvale, CA, USA). The intra-
and interassay coefficients of variation were below 7% and
9%, respectively. The detection limit of the test was 20 nM
and the limit of quantitation was 3000 nM. This measure-
ment was corrected for creatinine (NTX/creatinine). For
this correction, urinary creatinine was measured using a
rate-blanked modified Jaffe reaction. The intra- and inter-
assay coefficients of variation were 2.4% and 3.4%,
respectively, and the linear range was 3.6 to 650.0 mg/dl.
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was measured using an enzyme immunoassay kit (Serum
CrossLaps®, Immunodiagnostic Systems, Boldon, UK) on
an automated plate reader (Victor III ELISA Plate Reader,
PerkinElmer, Waltham, MA, USA). The intra- and inter-
assay coefficients of variation were below 15% and 10%,
respectively. The lower limit of detection was 0.01 ng/ml.
The bone turnover marker assays were performed at a
central laboratory (Pacific Biometrics, Seattle, WA, USA).
Safety assessments
Physical examinations were performed at baseline and after
52 weeks. Vital signs, concomitant medications, and
adverse event reports were recorded at regular clinic visits
throughout the study. Blood and urine samples for standard
laboratory measurements were collected at baseline and
after 13, 26, and 52 weeks of treatment. Serum chemistry
measurements were obtained after 14 days. Specimens were
analyzed by Quintiles Central Laboratory (Marietta, GA,
USA). Fecal occult blood samples were collected at
baseline and after 26 weeks, and 12-lead electrocardio-
grams were assessed at baseline and after 52 weeks.
Statistical analysis
The primary Endpoint analysis was a non-inferiority test
comparing the least squares mean percent change from
baseline in lumbar spine BMD in the DR weekly and the IR
daily groups after 52 weeks. The analysis followed a fixed-
sequence test procedure, with the first comparison being the
DR FB weekly group and the IR daily group. If, and only
if, the DR FB weekly group was declared non-inferior to
the IR daily group, the second comparison of the DR BB
weekly group versus the 5 mg IR daily group was
performed. The test employed a pre-defined non-
inferiority margin of 1.5% (chosen based on data from
previous risedronate studies) and a 1-sided type I error of
2.5%. The primary efficacy variable is the percent change
from baseline in lumbar spine BMD at Endpoint; the last
valid post-baseline measurement was used when the Week
52 value was missing (LOCF). The primary analysis
population was all subjects who were randomized, received
at least one dose of study drug, and had analyzable lumbar
spine BMD data at baseline and at least one post-treatment
time point. Investigative centers were pooled by geographic
region prior to unblinding. An analysis of variance
(ANOVA) was performed with treatment, anti-coagulation
medication use, and pooled centers as fixed effects, baseline
lumbar spine BMD as a covariate, and percent change from
baseline in lumbar spine BMD at Endpoint as the response
variable. As a secondary efficacy analysis, if the DR
weekly groups were both non-inferior to the IR daily
group, the DR weekly groups were pooled and a test of
their superiority to the IR daily group was performed using
ANOVA methods similar to those used for the primary
analysis. Other continuous secondary efficacy variables
were also analyzed using ANOVA methods similar to those
used for the primary analysis. Ninety-five percent, two-
sided confidence intervals (CIs) for the treatment difference
were constructed and used to determine differences be-
tween IR daily and each of the DR weekly treatment
groups. To assess the homogeneity of the treatment effects
across pooled centers, the percent change from baseline in
lumbar spine BMD at Endpoint was analyzed using an
ANOVA model with terms for treatment, baseline lumbar
spine BMD, anti-coagulant use, pooled center, and
treatment-by-pooled center interaction. Analysis of covari-
ance (ANCOVA) was performed using two separate models
to assess the effects of calcium and vitamin D supplement
levels and the corresponding interactions; average daily
dose was applied as the supplement level. The proportion of
patients with at least one new vertebral body fracture of the
thoracic or lumbar spine was compared to the IR daily
group using the Fisher’s exact test for each DR group
separately. The proportion of patients with adverse events
by category was compared across all treatment groups
using an overall Fisher’s exact test. Baseline characteristics
of the treatment groups were compared using one-way
ANOVA for continuous variables and Fisher’s exact test for
categorical variables.
Unless noted otherwise, all statistical analyses were two-
sided, with a type I error rate of 0.05, and no adjustments
were made for multiplicity.
Results
Subjects
From 1,859 women who were screened, 923 subjects were
randomized, and 922 subjects received at least one dose of
studydrug(Fig.1). Baseline characteristics were similar across
treatment groups (Table 1). A similar percentage of subjects in
each treatment group completed 12 months of the study (IR
daily group, 83.7%; DR FB weekly group, 82.1%; DR BB
weekly group, 83.8%). The most common reasons given for
withdrawal were adverse event and voluntary withdrawal,
which occurred at similar incidences across all three treatment
groups. Voluntary withdrawals were, by definition, unrelated
to adverse events and usually were attributed by the subject to
inconvenience or inability to travel to the clinic. A high
percentage of intent-to-treat subjects in all groups (94.8% of
subjects in the IR daily group, 96.1% of subjects in the DR
FB weekly group, and 91.9% of subjects in the DR BB
weekly group) took at least 80% of the study tablets.
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1859 
Randomized 
923 
Received 
5 mg daily IRBB 
307 
Received 
35 mg DRBB weekly  
308
Received 
35 mg DRFB weekly
307
Completed Year 1 
of study 
257
Completed Year 1 
of study 
258 
Completed Year 1 
of study 
252
Screen failures  936: 
  Did not meet BMD criteria  539 
  Withdrew consent  125   
  Did not meet lab criteria  122 
Withdrew before 
receiving drug 
1
Withdrawn: 
  Due to AEs  25 
  Lost to follow-up  3
  Voluntary  22 
Withdrawn: 
  Due to AEs  28 
  Lost to follow-up  2
  Voluntary  25 
Withdrawn: 
  Due to AEs  16 
  Inv. discretion  3 
  Lost to follow-up  4
  Voluntary  26 
Fig. 1 Disposition of subjects
Table 1 Summary of baseline characteristics
Risedronate
5 mg IR daily 35 mg DR FB weekly 35 mg DR BB weekly
(N=307) (N=307) (N=308)
Age (years), mean (SD) 65.3 (7.4) 65.8 (7.4) 66.0 (7.5)
Years since menopause, mean (SD) 17.5 (8.6) 18.2 (8.0) 18.8 (8.5)
Years since last menses (n [%])
5 to 10 years 78 (25.4) 60 (19.5) 62 (20.1)
More than 10 years 229 (74.6) 247 (80.5) 246 (79.9)
Race (n [%])
White 306 (99.7) 305 (99.3) 306 (99.4)
Asian (Oriental) 1 (0.3) 1 (0.3) 0 (0.0)
Multi-racial 0 (0.0) 1 (0.3) 2 (0.6)
Prevalent vertebral fracture (n [%]) 70 (24.1)
a 81 (28.2)
a 87 (29.1)
a
Standardized
b lumbar spine bone BMD (mg/cm
2), mean (SD) 762 (60) 763 (68) 763 (73)
Lumbar spine BMD T-score, mean (SD) −3.12 (0.52) −3.11 (0.59) −3.11 (0.56)
Standardized
b total proximal femur BMD (mg/cm
2), mean (SD) 591 (178) 593 (162) 593 (171)
Proximal femur BMD T-score, mean (SD) −2.96 (1.44) −2.95 (1.32) −2.94 (1.39)
Urinary NTX/creatinine (nmol BCE/mmol creatinine), mean (SD) 76.1 (33.0) 74.8 (36.1) 72.7 (33.7)
Serum CTX (ng/mL). mean (SD) 0.643 (0.272) 0.642 (0.288) 0.671 (0.849)
Serum BAP (μg/L), mean (SD) 28.6 (9.6) 27.3 (8.4) 27.5 (8.4)
BAP bone-specific alkaline phosphatase, BB before breakfast, BMD bone mineral density, CTX type-1 collagen cross-linked C-telopeptide, DR
delayed-release, FB following breakfast, IR immediate-release, NTX type-1 collagen cross-linked N-telopeptide corrected for creatinine
aPercent is based upon the number of subjects with known vertebral fracture status (5 mg IR daily group, 291; 35 mg DRFB weekly group, 287;
35 mg DRBB weekly group, 299)
bAdjusted to account for machine type [10]
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The least squares mean percent change (95% CI) from
baseline in lumbar spine BMD at Endpoint was 3.3%
(2.89% to 3.72%) in the DR FB weekly group and 3.1%
(2.66% to 3.47%) in the IR daily group, indicating both
groups experienced significant improvement from baseline
in lumbar spine BMD (Fig. 2). The difference between the
IR daily group and the DR FB group was −0.233%, with a
95% CI of −0.812% to 0.345%. The upper limit of the CI
for the difference between the groups was less than the pre-
defined non-inferiority margin of 1.5%. Therefore, the
35 mg DR tablet, when taken once a week after breakfast,
was determined to be non-inferior to the 5 mg IR daily
regimen with respect to percent changes in lumbar spine
BMD. The least squares mean percent change (95% CI)
from baseline in lumbar spine BMD at Endpoint for the DR
BB weekly group was 3.4% (2.96% to 3.77%), indicating
the DR BB group experienced significant improvement
from baseline in lumbar spine BMD. The difference
between the IR daily group and the DR BB weekly group
was −0.296%, with a 95% CI of −0.869% to 0.277%. As
for the DR FB weekly group, the upper limit of the CI for
the difference between the IR daily group and the DR BB
group was less than the pre-defined non-inferiority margin
of 1.5%; therefore, the 35 mg DR tablet, when taken once a
week at least 30 min before breakfast, was also deemed to
be non-inferior to the 5 mg IR daily regimen with respect to
percent changes in lumbar spine BMD. The treatment-by-
pooled center interaction was not significant, indicating the
treatment effect was consistent across geographies. When
the DR weekly groups are combined, the 35 mg DR weekly
regimen was determined not to be superior to the 5 mg IR
daily regimen. There were no statistically significant
differences between either of the DR weekly groups and
the IR daily group in mean percent change from baseline in
lumbar spine BMD at any time point (i.e., Week 26, Week
52, or Endpoint). There were no significant interactions
between treatment and the average daily dose of either
calcium or vitamin D supplements (p>0.1), indicating that
the treatment effect was consistent across calcium or
vitamin D supplement levels.
Significant increases from baseline in BMD at sites in
the hip (total proximal femur, femoral neck, femoral
trochanter) were observed at 26 and 52 weeks and Endpoint
in all treatment groups (Fig. 2). As was the case for lumbar
spine BMD, there were no statistically significant differ-
ences between either of the DR weekly regimens and the IR
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Fig. 2 Mean percent change from baseline ±SE in BMD over 1 year
in women receiving risedronate 5 mg IR daily , 35 mg DRFB
weekly , or 35 mg DRBB weekly . The Endpoint
value is calculated using LOCF at Week 52. Asterisk statistically
significant difference between IR daily and each of the DR weekly
treatment groups
272 Osteoporos Int (2012) 23:267–276daily regimen at any time point for the total proximal femur
and the femoral trochanter. At the femoral neck, no
statistically significant differences were seen between the DR
FBweeklyandtheIRdailygroupsatanytime point;however,
statisticallygreaterincreasesinBMDatWeek52andEndpoint
were seen in the DR BB weekly group compared to the IR
daily group (least squares mean difference in percent change
from baseline at Endpoint=−0.537; 95% CI −1.000, −0.074).
Significant decreases from baseline in NTX/creatinine, CTX,
and BAP were observed at 13, 26, and 52 weeks in all
treatment groups (Fig. 3). Small differences were observed
in the responses of resorption markers between the DR
weekly groups and the IR daily group. Compared to the
IR daily regimen, the decrease in urinary NTX/creati-
nine was statistically greater with DR FB weekly dosing
at Week 52 and Endpoint, and the reduction in serum
CTX was significantly greater in the DR FB weekly
group at Weeks 26 and 52 and at Endpoint and with the
DR BB dose at Endpoint.
New incident morphometric vertebral fractures during
the first 52 weeks of treatment occurred in two subjects in
the IR daily group, 2 subjects in the DR FB weekly group,
and 3 subjects in the DR BB weekly group. There were no
statistically significant differences between either of the DR
weekly groups and the IR daily group.
Safety assessments
Overall, the adverse event profile was similar across the
three treatment groups during the first 52 weeks of
treatment (Table 2). The incidence of upper gastrointestinal
adverse events was numerically but not significantly higher
in the DR BB weekly group than in the IR daily or DR FB
weekly groups, mostly due to a significantly higher
incidence of upper abdominal in the DR BB group
(p value=0.0041). These events were all judged to be mild
or moderate. The incidence of lower gastrointestinal
adverse events was slightly but not significantly higher in
the DR FB weekly group than in the IR daily or DR BB
weekly groups, mostly due to events of mild to moderate
diarrhea. The frequency of gastrointestinal adverse events
with daily IR risedronate and the DR doses in this study is
consistent with previous studies of daily, weekly, and
monthly dosing with risedronate [11–13].
Other adverse events of special interest for bisphospho-
nates include clinical fractures, musculoskeletal adverse
events, and acute phase reaction adverse events. Clinical
fractures are defined as all nonvertebral fractures and
symptomatic, radiographically confirmed vertebral fractures
that occurred after randomization and were reported as
adverse events. Acute phase reactions are defined as
Urine NTX/Cr
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Fig. 3 Mean percent change from baseline ±SE in bone turnover
markers over 1 year in women receiving risedronate 5 mg IR daily
,3 5m gD R F Bw e e k l y ,o r3 5m gD R B B
weekly . The Endpoint value is calculated using LOCF at Week
52. Asterisk statistically significant difference between IR daily and
each of the DR weekly treatment groups
Osteoporos Int (2012) 23:267–276 273influenza-like illness and/or pyrexia starting within 3 days
following the first dose of study drug and having a duration
of 7 days or less. Clinical vertebral and nonvertebral
fractures occurred infrequently. The numeric differences
noted were not statistically significant, and the types of
fractures were similar among the treatment groups. Muscu-
loskeletal adverse events were reported by similar propor-
tions of subjects across treatment groups (Table 2). No
cases of acute phase reaction or osteonecrosis of the jaw
were reported.
Small decreases in serum calcium and the expected
reciprocal increases in serum iPTH 1–84 were seen within
the first few weeks of treatment, as expected upon initiation
of antiresorptive therapy. These changes were transient and
were not symptomatic or clinically meaningful. No clini-
cally important differences were seen across groups for any
laboratory parameter measured, including measures of
hepatic and renal function.
Other laboratory safety parameters, including fecal
occult blood tests, coagulation parameters, and electro-
cardiograms, revealed no adverse safety signals.
Discussion
Risedronate, as an IR tablet, has proven vertebral and
nonvertebral antifracture efficacy. Due to poor bioavailabil-
ity in the presence of food with all bisphosphonates, it is
important that these medications be taken before the first
food or drink of the day for optimal efficacy. With
risedronate, patients must wait at least 30 min after dosing
before eating or drinking anything other than water. This
study has shown that the novel risedronate 35 mg DR
tablet, when taken once weekly either before or after
breakfast, produces clinical effects similar to those seen
with the risedronate 5 mg IR tablet taken daily as
Table 2 Summary of adverse events
Risedronate
5 mg IR daily 35 mg DR FB weekly 35 mg DR BB weekly
(N=307) (N=307) (N=308)
n (%) n (%) n (%)
Adverse events 211 (68.7) 222 (72.3) 238 (77.3)
Serious adverse events 22 (7.2) 20 (6.5) 21 (6.8)
Deaths 1 (0.3) 0 (0.0) 0 (0.0)
Withdrawn due to an adverse event 25 (8.1) 28 (9.1) 19 (6.2)
Most common adverse events associated with withdrawal
Gastrointestinal disorder 11 (3.6) 17 (5.5) 13 (4.2)
Most common adverse events
Influenza 19 (6.2) 22 (7.2) 18 (5.8)
Nasopharyngitis 16 (5.2) 21 (6.8) 26 (8.4)
Arthralgia 24 (7.8) 21 (6.8) 19 (6.2)
Back pain 18 (5.9) 21 (6.8) 19 (6.2)
Adverse events of special interest
Clinical vertebral fracture 1 (0.3) 0 (0.0) 2 (0.6)
Clinical nonvertebral fracture 5 (1.6) 9 (2.9) 10 (3.2)
Upper gastrointestinal tract adverse events 45 (14.7) 48 (15.6) 61 (19.8)
Diarrhea 15 (4.9) 27 (8.8) 18 (5.8)
Abdominal pain 9 (2.9) 16 (5.2) 15 (4.9)
Upper abdominal pain
a 7 (2.3) 9 (2.9) 23 (7.5)
Constipation 9 (2.9) 15 (4.9) 16 (5.2)
Selected musculoskeletal adverse events
b 46 (15.0) 48 (15.6) 53 (17.2)
Adverse events potentially associated with acute phase reaction
c 4 (1.3) 7 (2.3) 4 (1.3)
ap value=0.0041
bIncludes arthralgia, back pain, bone pain, musculoskeletal pain, musculoskeletal discomfort, myalgia, and neck pain
cIncludes symptoms of influenza-like illness or pyrexia with a start date within the first 3 days after the first dose of study drug and duration of
7 days or less
274 Osteoporos Int (2012) 23:267–276prescribed. Specifically, the mean percent changes in
lumbar spine BMD at 52 weeks in the DR weekly groups
were non-inferior to the mean percent change in the IR
daily group. Changes in secondary efficacy parameters,
including BMD at the hip, bone turnover markers and new
morphometric vertebral fractures were generally similar in
both DR weekly groups compared to the IR daily group.
Statistically significant increases in femoral neck BMD, and
decreases in bone turnover markers, were seen at some time
points in the DR weekly groups compared to the IR daily
group. The reason for the somewhat increased responses to
the DR regimen is unclear but is probably not explained by
the difference in daily versus weekly dosing since the BMD
and marker responses to daily and weekly risedronate IR
did not differ [14]. Even a modestly better bioavailability of
the DR formulation compared to IR during the year of
therapy could account for the difference. Alternatively,
perhaps compliance with dosing instructions was better
with the weekly DR regimen compared to the daily IR
regimen, even in the context of clinical trial where
compliance with therapy is generally better than in daily
clinical practice.
The risedronate DR weekly regimen was generally well
tolerated by postmenopausal women, with a safety profile
similar to that seen with the risedronate daily regimen.
Although upper abdominal pain and diarrhea were more
frequent in the DR weekly groups, few subjects withdrew
due to the events. Most events were mild or moderate in
severity, suggesting these symptoms with the 35 mg DR
weekly regimen will have a minimal impact on adherence
to treatment in clinical use.
The vertebral and nonvertebral antifracture efficacy of
risedronate has been established in multiple large studies
that had fracture as the primary Endpoint [12, 15, 16]. BMD
change is an appropriate surrogate Endpoint when evaluat-
ing a new dosing regimen for a bisphosphonate for which a
fracture benefit has already been established. Similar non-
inferiority trials have been conducted previously to evaluate
new dosing regimens of oral and intravenous bisphospho-
nates [11, 17, 18], and this approach has been accepted by
both the United States Food and Drug Administration and
the European Medicines Agency [14] for approval of new
regimens of established agents. The Year 1 BMD results
observed in this study are consistent with what has been
observed in the pivotal antifracture studies and other
previous studies of risedronate IR weekly and monthly
dosing regimens [11, 13, 19].
These results were obtained with specific dosing
regimens. The data presented here pertain only to
dosing with risedronate DR at least 30 min before or
immediately after breakfast and may not reflect the
responses to taking the new formulation at other times.
It is also important to note that calcium supplements
were taken at a time of day different than the
risedronate doses and that the effect of taking calcium
supplements around the time of breakfast on the day the
DR formulation was taken is not known. All subjects
w e r er e q u i r e dt or e m a i nu p r i g h ta f t e rt a k i n gt h es t u d y
tablets since they might have been taking risedronate
IR. As a result, the requirement to remain upright after
dosing persists with risedronate DR. In theory, having
the DR formulation disintegrate in the small intestine
rather than the esophagus or stomach should decrease
the potential for reflux of the drug into the esophagus
and esophageal irritation. The study was not designed to
evaluate that outcome.
In summary, the risedronate 35 mg DR weekly dosing
regimen, taken before or following breakfast, was similar in
efficacy and tolerability to risedronate 5 mg IR daily dosing
in postmenopausal women with osteoporosis. By minimiz-
ing the impact of concomitantly ingested food on the
bioavailability of risedronate, the 35 mg DR tablet, taken in
the morning once a week without regard to food or drink,
could make it easier for patients to accept and comply with
therapy, thus improving the effectiveness of risedronate in
clinical practice. Risedronate 35 mg as a delayed-release
tablet taken once weekly before or after breakfast provides
a simplified dosing regimen for the patient while ensuring
the full efficacy of risedronate.
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